JM Financial recommends buying Piramal Pharma stock. The target price is Rs 340. The current market price is Rs 260.55. India’s CRDMO industry is expected to double by 2028. Piramal Pharma is well-positioned for growth. The company’s CDMO business is a key driver. JM Financial projects a 15% topline growth and 23%+ EBITDA CAGR over FY24-27.
